The researchers focused on antibodies that target these sites because of their potential to be highly effective across different lineages of a virus. But there are often sites on the virus that remain unchanged despite mutations. When viruses mutate, many binding sites are altered or eliminated, leaving antibodies ineffectual. They identified more than 1,700 antibodies, which the immune system produces to bind at specific sites on specific viruses to block the pathogen from infecting cells. Haynes and colleagues at DHVI isolated the antibody by analyzing the blood from a patient who had been infected with the original SARS-CoV-1 virus, which caused the SARS outbreak in the early 2000s, and from a current COVID-19 patient. “It could also be available for future outbreaks, if or when other coronaviruses jump from their natural animal hosts to humans.” “This antibody has the potential to be a therapeutic for the current epidemic,” said co-senior author Dr. 2 in the journal Science Translational Medicine. Researchers published their findings Nov. The antibody was identified by a team at the Duke Human Vaccine Institute and tested in animal models at UNC-Chapel Hill. University Development Opens in new siteĪ research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.Gillings School of Global Public Health.News and Updates Display Sub Menu for News and Updates.Life at Carolina Display Sub Menu for Life at Carolina.Athletics Display Sub Menu for Athletics.Continuing Education Opportunities Opens in new site.Academics Display Sub Menu for Academics.
0 Comments
Leave a Reply. |